At the American Society of Hematology (ASH) 2011, Carlo Gambacorti-Passerini, MD, Professor of Internal Medicine at the University of Milano Bicocca, and Director of the Clinical Research Unit, San Gerardo Hospital in Monza, Italy, discusses bosutinib versus imatinib in newly diagnosed chronic phase chronic myeloid leukemia — BELA Trial: 24-month follow-up

свернуть